Advertisement

Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group

Published:October 16, 2019DOI:https://doi.org/10.1016/j.jinf.2019.10.007

      Highlights

      • Consensus view from Public Health England's HCV Resistance Group.
      • Review providing guidance on when and how to perform HCV resistance testing, and interpretation of results.
      • Includes five key scenarios where HCV resistance testing is recommended in the UK and other similar settings.

      Abstract

      The treatment of hepatitis C virus (HCV) infection has been revolutionised by the advent of oral, well-tolerated, direct acting antiviral therapies (DAA), with high cure rates. However, in some scenarios, HCV resistance to antiviral therapies may have an impact on treatment success. Public Health England's HCV Resistance Group was established to support clinicians treating people with HCV, where the issue of resistance may be a factor in clinical decision-making, and this review includes the Group's current recommendations on the use of HCV resistance testing. The authors describe the principles behind and approach to HCV resistance testing and consider evidence from in vitro studies, clinical trials and real world cohorts on the impact of HCV resistance on treatment outcomes for particular DAA regimens. Five scenarios are identified in the UK and similar settings, where, in the Group's opinion, resistance testing should be performed.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • EASL recommendations on treatment of hepatitis C 2018
        J Hepatol. 2018; 69: 461-511
        • AASLD-IDSA
        HCV guidance: recommendations for testing, managing, and treating hepatitis C.
        Clin Infect Dis. 2018; 67: 1477-1492
      1. Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis 2016 [Available from:http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1.

        • Neumann A.U.
        • Lam N.P.
        • Dahari H.
        • Gretch D.R.
        • Wiley T.E.
        • Layden T.J.
        • et al.
        Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
        Science. 1998; 282: 103-107
        • Cuevas J.M.
        • Gonzalez-Candelas F.
        • Moya A.
        • Sanjuan R.
        Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo.
        J Virol. 2009; 83: 5760-5764
        • Zeuzem S.
        • Mizokami M.
        • Pianko S.
        • Mangia A.
        • Han K.H.
        • Martin R.
        • et al.
        NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome.
        J Hepatol. 2017; 66: 910-918
        • Sarrazin C.
        • Dvory-Sobol H.
        • Svarovskaia E.S.
        • Doehle B.P.
        • Pang P.S.
        • Chuang S.M.
        • et al.
        Prevalence of resistance-associated substitutions in Hcv NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir.
        Gastroenterology. 2016; 151 (e1): 501-512
        • Krishnan P.
        • Tripathi R.
        • Schnell G.
        • Reisch T.
        • Beyer J.
        • Irvin M.
        • et al.
        Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
        Antimicrob Agents Chemother. 2015; 59: 5445-5454
        • Gane E.J.
        • Metivier S.
        • Nahass R.
        • Ryan M.
        • Stedman C.A.
        • Svarovskaia E.S.
        • et al.
        The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.
        Hepatol Commun. 2017; 1: 538-549
        • Popping S.
        • Cento V.
        • Boucher C.A.B.
        • Wensing A.
        • Devaux C.
        • Salmon D.
        • et al.
        Prevalence of NS3 and NS5A resistance associated substitutions through European DAA-failures.
        AASLD, San Francisco, USA2018
        • Wyles D.
        • Mangia A.
        • Cheng W.
        • Shafran S.
        • Schwabe C.
        • Ouyang W.
        • et al.
        Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.
        Antivir Ther. 2018; 23: 229-238
      2. Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated variants (RAVs) after treatment with grazoprevir-containing regimens in patients with chronic hepatitis C virus (HCV) infection.
        in: Lahser F.C. Galloway A. Hwang P. Palcza J. Wahl J. Robertson M. American Association for the Study of Liver Diseases, Boston2016
        • Singer J.B.
        • Thomson E.C.
        • McLauchlan J.
        • Hughes J.
        • Gifford R.J.
        GLUE: a flexible software system for virus sequence data.
        BMC Bioinform. 2018; 19: 532
        • Sorbo M.C.
        • Cento V.
        • Di Maio V.C.
        • Howe A.Y.M.
        • Garcia F.
        • Perno C.F.
        • et al.
        Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018.
        Drug Resist Updat. 2018; 37: 17-39
        • Komatsu T.E.
        • Boyd S.
        • Sherwat A.
        • Tracy L.
        • Naeger L.K.
        • O'Rear J.J.
        • et al.
        Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir.
        Gastroenterology. 2017; 152: 586-597
        • Hezode C.
        • Reau N.
        • Svarovskaia E.S.
        • Doehle B.P.
        • Shanmugam R.
        • Dvory-Sobol H.
        • et al.
        Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 studies.
        J Hepatol. 2018; 68: 895-903
        • Borgia S.M.
        • Hedskog C.
        • Parhy B.
        • Hyland R.H.
        • Stamm L.M.
        • Brainard D.M.
        • et al.
        Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes.
        J Infect Dis. 2018; 218: 1722-1729
      3. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., et al. International committee on taxonomy of viruses (ICTV). HCV Classification2017[Available from: Available at:https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification.

        • Thomson E.
        • Ip C.L.
        • Badhan A.
        • Christiansen M.T.
        • Adamson W.
        • Ansari M.A.
        • et al.
        Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes.
        J Clin Microbiol. 2016; 54: 2470-2484
        • Chevaliez S.
        • Bouvier-Alias M.
        • Brillet R.
        • Pawlotsky J.M.
        Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.
        PLoS One. 2009; 4: e8209
        • da Silva Filipe A.
        • Sreenu V.
        • Hughes J.
        • Aranday-Cortes E.
        • Irving W.L.
        • Foster G.R.
        • et al.
        Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries.
        J Hepatol. 2017; 67: 1348-1350
        • Li C.
        • Njouom R.
        • Pepin J.
        • Nakano T.
        • Bennett P.
        • Pybus O.G.
        • et al.
        Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1.
        J Gen Virol. 2013; 94: 1780-1790
        • Wei L.
        • Lim S.G.
        • Xie Q.
        • Van K.N.
        • Piratvisuth T.
        • Huang Y.
        • et al.
        Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
        Lancet Gastroenterol Hepatol. 2019; 4: 127-134
        • Gupta N.
        • Mbituyumuremyi A.
        • Kabahizi J.
        • Ntaganda F.
        • Muvunyi C.M.
        • Shumbusho F.
        • et al.
        Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir–sofosbuvir (SHARED): a single-arm trial.
        Lancet Gastroenterol Hepatol. 2019; 4: 119-126
        • Camus G.
        • Han B.
        • Asselah T.
        • Hsieh D.
        • Dvory-Sobol H.
        • Lu J.
        • et al.
        Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4.
        J Viral Hepat. 2018; 25: 134-143
        • Fourati S.
        • Rodriguez C.
        • Hezode C.
        • Soulier A.
        • Ruiz I.
        • Poiteau L.
        • et al.
        Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.
        Hepatology. 2019; 69: 513-523
        • Gededzha M.P.
        • Selabe S.G.
        • Kyaw T.
        • Rakgole J.N.
        • Blackard J.T.
        • Mphahlele M.J.
        Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa.
        J Med Virol. 2012; 84: 601-607
        • Hundie G.B.
        • Raj V.S.
        • GebreMichael D.
        • Pas S.D.
        • Haagmans B.L.
        Genetic diversity of hepatitis C virus in Ethiopia.
        PLoS One. 2017; 12e0179064
        • Mettikanont P.
        • Bunchorntavakul C.
        • Reddy K.R.
        Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.
        Aliment Pharmacol Ther. 2019; 49: 492-505
        • Davis C.
        • Mgomella G.S.
        • da Silva Filipe A.
        • Frost E.H.
        • Giroux G.
        • Hughes J.
        • et al.
        Highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments.
        Hepatology. 2019; 69: 1426-1441
        • Susser S.
        • Dietz J.
        • Schlevogt B.
        • Zuckerman E.
        • Barak M.
        • Piazzolla V.
        • et al.
        Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
        J Hepatol. 2017; 67: 680-686
        • Janiak M.
        • Caraballo Cortes K.
        • Perlejewski K.
        • Kubicka-Russel D.
        • Grabarczyk P.
        • Demkow U.
        • et al.
        Next-generation sequencing of hepatitis C virus (HCV) mixed-genotype infections in anti-HCV-negative blood donors.
        Adv Exp Med Biol. 2018; 1096: 65-71
        • Cunningham E.B.
        • Applegate T.L.
        • Lloyd A.R.
        • Dore G.J.
        • Grebely J.
        Mixed HCV infection and reinfection in people who inject drugs – impact on therapy.
        Nat Rev Gastroenterol Hepatol. 2015; 12: 218-230
        • Abdelrahman T.
        • Hughes J.
        • Main J.
        • McLauchlan J.
        • Thursz M.
        • Thomson E.
        Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.
        Hepatology. 2015; 61: 88-97
        • Midgard H.
        • Weir A.
        • Palmateer N.
        • Lo Re 3rd, V.
        • Pineda J.A.
        • Macias J.
        • et al.
        HCV epidemiology in high-risk groups and the risk of reinfection.
        J Hepatol. 2016; 65: S33-S45
        • Ingiliz P.
        • Martin T.C.
        • Rodger A.
        • Stellbrink H.J.
        • Mauss S.
        • Boesecke C.
        • et al.
        HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.
        J Hepatol. 2017; 66: 282-287
        • Simmons B.
        • Saleem J.
        • Hill A.
        • Riley R.D.
        • Cooke G.S.
        Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis.
        Clin Infect Dis. 2016; 62: 683-694
        • Aldridge R.W.
        • Hayward A.C.
        • Hemming S.
        • Yates S.K.
        • Ferenando G.
        • Possas L.
        • et al.
        High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population.
        Thorax. 2018; 73: 557-564
      4. Public Health England. Hepatitis C in England: 2018 report 2018 [Available from:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/693917/HCV_in_England_2018.pdf.

        • Bourliere M.
        • Bronowicki J.P.
        • de Ledinghen V.
        • Hezode C.
        • Zoulim F.
        • Mathurin P.
        • et al.
        Ledipasvir–sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
        Lancet Infect Dis. 2015; 15: 397-404
        • Drysdale K.
        • Foster G.R.
        • Townley C.
        • Mahomed F.
        Real-world effectiveness of directly-acting antiviral treatments in England: data on all treated patients from the national registry.
        British Association for the Study of the Liver, York, UK2018 (19/09/2018)
        • Abergel A.
        • Metivier S.
        • Samuel D.
        • Jiang D.
        • Kersey K.
        • Pang P.S.
        • et al.
        Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
        Hepatology. 2016; 64: 1049-1056
        • Gane E.J.
        • Hyland R.H.
        • An D.
        • Svarovskaia E.
        • Pang P.S.
        • Brainard D.
        • et al.
        Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
        Gastroenterology. 2015; 149 (e1): 1454-1461
        • Abergel A.
        • Asselah T.
        • Metivier S.
        • Kersey K.
        • Jiang D.
        • Mo H.
        • et al.
        Ledipasvir–sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
        Lancet Infect Dis. 2016; 16: 459-464
        • Nguyen E.
        • Trinh S.
        • Trinh H.
        • Nguyen H.
        • Nguyen K.
        • Do A.
        • et al.
        Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
        Aliment Pharmacol Ther. 2019; 49: 99-106
        • Gottwein J.M.
        • Pham L.V.
        • Mikkelsen L.S.
        • Ghanem L.
        • Ramirez S.
        • Scheel T.K.H.
        • et al.
        Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants.
        Gastroenterology. 2018; 154: 1435-1448
        • Liu R.
        • Curry S.
        • McMonagle P.
        • Yeh W.W.
        • Ludmerer S.W.
        • Jumes P.A.
        • et al.
        Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
        Antimicrob Agents Chemother. 2015; 59: 6922-6929
        • Lahser F.C.
        • Bystol K.
        • Curry S.
        • McMonagle P.
        • Xia E.
        • Ingravallo P.
        • et al.
        The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons.
        Antimicrob Agents Chemother. 2016; 60: 2954-2964
        • Harrington P.R.
        • Komatsu T.E.
        • Deming D.J.
        • Donaldson E.F.
        • O'Rear J.J.
        • Naeger L.K.
        Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: regulatory analyses and perspectives.
        Hepatology. 2018; 67: 2430-2448
        • Serfaty L.
        • Jacobson I.
        • Rockstroh J.
        • Altice F.L.
        • Hwang P.
        • Barr E.
        • et al.
        The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.
        J Viral Hepat. 2019; 26: 329-336
      5. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier European association for the study of the liver.
        in: Cheng G. Tian Y. Yu M. Lee Y.-J. Gong R. Trejo-Martin A. Amsterdam, The Netherlands2013 (24–28 April 2013)
        • Dvory-Sobol H.
        • Han B.
        • Lu J.
        • Yu M.
        • Beran R.K.
        • Cheng G.
        • et al.
        In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
        J Viral Hepat. 2019; 26: 991-1001
        • Foster G.R.
        • Afdhal N.
        • Roberts S.K.
        • Brau N.
        • Gane E.J.
        • Pianko S.
        • et al.
        Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.
        N Engl J Med. 2015; 373: 2608-2617
        • Roberts S.K.
        • Buti M.
        • Foster G.R.
        • Calleja J.L.
        • Sood A.
        • Isakov V.A.
        • et al.
        Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: an integrated analysis of phase 2 and phase 3 clinical trials.
        AASLD, San Francisco, USA2018
      6. Safety and efficacy of sofosbuvir/velpatasvir with and without ribavirin in genotype 3 HCV-infected patients with cirrhosis.
        in: Buti M. Pineda J.A. Calleja J.L. Rodrigues M. Morillas R.M. Acevedo J.M.P. European Association for the Study of the Liver, Paris, France2018 (11–15 April)
        • von Felden J.
        • Vermehren J.
        • Ingiliz P.
        • Mauss S.
        • Lutz T.
        • Simon K.G.
        • et al.
        High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.
        Aliment Pharmacol Ther. 2018; 47: 1288-1295
        • Curry M.P.
        • O'Leary J.G.
        • Bzowej N.
        • Muir A.J.
        • Korenblat K.M.
        • Fenkel J.M.
        • et al.
        Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.
        N Engl J Med. 2015; 373: 2618-2628
        • Kong X.
        • Wei L.
        • Yang R.
        • Rao H.
        • Zhang H.
        • Wan J.
        • et al.
        The presence of resistance-associated substitutions (A30K+L31M) in DAA treatment-Naïve patients with genotype-3b HCV infection.
        AASLD, San Francisco, USA2018
      7. Antiviral resistance testing in the management of hepatitis C virus infection: Public Health England; 2018[Available from:https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/762347/Antiviral_resistance_testing_in_the_management_of_hepatitis_C_virus_infection.pdf.

      8. AbbVie. Summary of product characteristics: maviret 100 mg/40 mg film coated tablets 2019 [updated 02/09/2019. Available from:https://www.medicines.org.uk/emc/product/763/smpc.

        • Poordad F.
        • Felizarta F.
        • Asatryan A.
        • Sulkowski M.S.
        • Reindollar R.W.
        • Landis C.S.
        • et al.
        Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
        Hepatology. 2017; 66: 389-397
        • Poordad F.
        • Pol S.
        • Asatryan A.
        • Buti M.
        • Shaw D.
        • Hezode C.
        • et al.
        Glecaprevir/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure.
        Hepatology. 2017; 67: 1253-1260
        • Sarrazin C.
        • Cooper C.L.
        • Manns M.P.
        • Reddy K.R.
        • Kowdley K.V.
        • Roberts S.K.
        • et al.
        No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12weeks in HCV DAA-experienced patients.
        J Hepatol. 2018; 69: 1221-1230
      9. Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies.
        in: Reau N. Nguyen M.H. Kowdley K.V. Gane E.J. Dvory-Sobol H. Svarovskaia E. Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies. American Association for the Study of Liver Diseases, Boston2016
        • Hezode C.
        • Guyader D.
        • Nguyen B.Y.
        • Larrey D.
        • Di Martino V.
        • Minello-Franza A.
        • et al.
        Sofosbuvir/velpatasvir/voxilaprevir in DAA failure patients with cirrhosis.
        Final Results of the French Compassionate Use Program AASLD, San Francisco, USA2018
        • Covert E.
        • Hoffmann J.
        • Emmanuel B.
        • Comstock E.
        • Tang L.
        • Kattakuzhy S.
        • et al.
        Retreatment with SOF/VEL/VOX in treatment-experienced patients with and without HIV: the RESOLVE study.
        AASLD, San Francisco, USA2018
        • Bacon R.B.
        • Curry M.P.
        • Flamm S.
        • Milligan S.
        • Tsai N.C.S.
        • Wick N.
        • et al.
        Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the trio network.
        AASLD, San Francisco, USA2018
        • Backus L.I.
        • Belperio P.S.
        • Shahoumian T.A.
        • Loomis T.P.
        • Winters M.A.
        • Holodniy M.
        Real-world impact of resistance-associated substitutions on re-treatment after ledipasvir/sofosbuvir virologic failure in hepatitis C patients.
        AASLD, San Francisco, USA2018
        • Saxena V.
        • Chamberland S.
        • Hurley L.
        • Lai J.B.
        • Truong E.
        • Marcus J.
        • et al.
        Real-world safety and effectiveness of sofosbuvir/velpatasvir/voxilaprevir and glecaprevir/pibrentasvir in hepatitis C infected patients.
        AASLD, San Francisco, USA2018: 705
        • Vermehren J.
        • Dietz J.
        • Peiffer K.-.H.
        • Zeuzem S.
        • Sarrazin C.
        Resistance analysis in direct acting antiviral-experienced patients with chronic hepatitis C virus infection treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) – results from the Frankfurt resistance database.
        AASLD, San Francisco, USA2018
        • Llaneras J.
        • Riveiro-Barciela M.
        • Lens S.
        • Diago M.
        • Cachero A.
        • Garcia-Samaniego J.
        • et al.
        Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
        J Hepatol. 2019; 71: 666-672
        • Belperio P.S.
        • Shahoumian T.A.
        • Loomis T.P.
        • Backus L.I.
        Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
        J Viral Hepat. 2019; 26: 980-990
        • Vermehren J.
        • Stoehr A.
        • Schulze Zur Wiesch J.
        • Klinker H.
        • Cornberg M.
        • Jung M.-.C.
        • et al.
        Retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure – results from the German Hepatitis C-Registry (DHC-R).
        AASLD, San Francisco, USA2018
      10. Degasperi E., Spinetti A., Lombardi A., Landonio S., Rossi M.C., Pasulo L., et al. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol 2019 pii: S0168-8278.

        • Pearlman B.
        • Perrys M.
        • Hinds A.
        Sofosbuvir/Velpatasvir/Voxilaprevir for previous treatment failures with glecaprevir/pibrentasvir in chronic hepatitis C infection.
        Am J Gastroenterol. 2019; 114: 1550-1552
        • Poordad F.
        • Pol S.
        • Asatryan A.
        • Buti M.
        • Shaw D.
        • Hezode C.
        • et al.
        Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
        Hepatology. 2018; 67: 1253-1260
        • Lok A.S.
        • Sulkowski M.S.
        • Kort J.J.
        • Willner I.
        • Reddy K.R.
        • Shiffman M.L.
        • et al.
        Efficacy of glecaprevir and pibrentasvir in patients with genotype 1 hepatitis C virus infection with treatment failure after NS5A inhibitor plus sofosbuvir therapy.
        Gastroenterology. 2019; (pii: S0016-5085)
        • Uemura H.
        • Uchida Y.
        • Kouyama J.I.
        • Naiki K.
        • Tsuji S.
        • Sugawara K.
        • et al.
        NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
        J Gastroenterol. 2019; 54: 459-470
        • Osawa M.
        • Imamura M.
        • Teraoka Y.
        • Uchida T.
        • Morio K.
        • Fujino H.
        • et al.
        Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
        J Gastroenterol. 2019; 54: 291-296
        • Gane E.J.
        • Shiffman M.L.
        • Etzkorn K.
        • Morelli G.
        • Stedman C.A.M.
        • Davis M.N.
        • et al.
        Sofosbuvir–velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
        Hepatology. 2017; 66: 1083-1089
        • Brancaccio G.
        • Martini S.
        • Ciancio A.
        • Volpes R.
        • Di Stefano M.
        • Masarone M.
        • et al.
        Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus (HCV) infection failing to a previous DAA combination regimen.
        AASLD, San Francisco, USA2018
        • Papaluca T.
        • Sinclair M.
        • Gow P.
        • Pianko S.
        • Sievert W.
        • Arachchi N.
        • et al.
        Retreatment with elbasvir, grazoprevir, sofosbuvir +/− ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
        Liver Int. 2019; https://doi.org/10.1111/liv.14201
        • Lawitz E.
        • Poordad F.
        • Gutierrez J.A.
        • Wells J.T.
        • Landaverde C.E.
        • Evans B.
        • et al.
        Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: a randomized trial.
        Hepatology. 2017; 65: 439-450
        • de Ledinghen V.
        • Laforest C.
        • Hezode C.
        • Pol S.
        • Renault A.
        • Alric L.
        • et al.
        Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: the ANRS HC34 revenge study.
        Clin Infect Dis Off Publ Infect Dis Soc Am. 2018; 66: 1013-1018
      11. Retreatment of hepatitis C virus infection in patients who failed glecaprevir/pibrentasvir.
        in: Wyles D. Weiland O. Yao R. Reindollar R. Weilert F. Dufour J.-F. Retreatment of hepatitis C virus infection in patients who failed glecaprevir/pibrentasvir. European Association for the Study of the Liver, Paris, France2018
        • Manns M.
        • Samuel D.
        • Gane E.J.
        • Mutimer D.
        • McCaughan G.
        • Buti M.
        • et al.
        Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
        Lancet Infect Dis. 2016; 16: 685-697